Abstracts Archive - Page 1894 of 2607 - ACR Meeting Abstracts

Abstract Number: 341 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Four Hand Mobility Measures in Hand Osteoarthritis (HOA)
Féline Kroon¹, Jessica Bijsterbosch¹, Ingrid Meulenbelt², Frits R. Rosendaal³, Désirée van der Heijde¹ and Margreet Kloppenburg^1,3, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Molecular Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ³Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The OMERACT HOA working group recently proposed ‘hand mobility' as an outcome measure in HOA trials, although no disease specific instruments are available yet.…
Abstract Number: 342 • 2015 ACR/ARHP Annual Meeting
The Effect of Erosive Status on Systemic Inflammatory Biomarkers in Hand Osteoarthritis
Alexander Mathiessen¹, Nina Østerås², Tore K. Kvien³, Hilde Berner Hammer⁴ and Ida K. Haugen⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology,, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵P.O. Box 23, Diakonhjemmet Hospital, Vinderen, Norway
Background/Purpose : It is debated whether erosive hand osteoarthritis (OA) is a separate inflammatory subset of hand OA, or just a severe form of the same…
Abstract Number: 343 • 2015 ACR/ARHP Annual Meeting
Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Kenneth G. Saag¹, Peter Alexandersen², Claude-Laurent Benhamou³, Nigel Gilchrist⁴, Johan Halse⁵, E. Michael Lewiecki⁶, Kurt Lippuner⁷, Michael McClung⁸, Masataka Shiraki⁹, Carolyn A. DaSilva¹⁰, Nadia Verbruggen¹¹, Boyd B. Scott¹⁰ and Antonio Lombardi¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ³Hôpital d’Orléans-la-Source, Orléans, France, Orleans, France, ⁴The Princess Margaret Hospital, Christchurch, New Zealand, Christchurch, New Zealand, ⁵Osteoporoseklinikken, Oslo, Norway, Oslo, Norway, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA, Albuquerque, NM, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸Oregon Osteoporosis Center, Portland, Oregon, USA, Portland, OR, ⁹Research Institute and Practice for Involutional Diseases, Nagano, Japan, Nagano, Japan, ¹⁰Merck & Co., Inc, Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term Odanacatib Fracture…
Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 345 • 2015 ACR/ARHP Annual Meeting
Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
S Ferrari¹, C Libanati², CJF Lin², S Adami³, JP Brown⁴, F Cosman⁵, E Czerwinski⁶, LH de Gregório⁷, J Malouf⁸, J-Y Reginster⁹, NS Daizadeh², A Wang², RB Wagman² and EM Lewiecki¹⁰, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: The relationship between BMD T-score and fracture risk has not been established in patients on therapy. We previously reported that denosumab (DMAb) treatment over…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 347 • 2015 ACR/ARHP Annual Meeting
Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
NB Watts¹, JP Brown², S Papapoulos³, EM Lewiecki⁴, DL Kendler⁵, P Dakin⁶, RB Wagman⁶, A Wang⁶, NS Daizadeh⁶, S Smith⁶ and HG Bone⁷, ¹Mercy Health, Cincinnati, OH, ²Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Denosumab (DMAb) is approved for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. In the pivotal 3-year FREEDOM trial comparing…
Abstract Number: 348 • 2015 ACR/ARHP Annual Meeting
Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates
Fei Xue¹, Rachel B Wagman¹, Susan Yue¹, Shawna Smith¹, Tarun Arora², Jeffrey R. Curtis², Vera Ehrenstein³, Henrik T Sørensen³, Grethe Tell⁴, Helle Kieler⁵, Florence T Wang⁶, David D Dore⁶ and J Michael Sprafka¹, ¹Amgen Inc., Thousand Oaks, CA, ²University of Alabama at Birmingham, Birmingham, AL, ³Aarhus University Hospital, Aarhus, Denmark, ⁴University of Bergen, Bergen, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Optum, Waltham, MA
Background/Purpose: Although a higher risk of osteonecrosis of the jaw (ONJ) has been associated with antiresportive treatment based on spontaneous reports and observational studies, no…
Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…
Abstract Number: 350 • 2015 ACR/ARHP Annual Meeting
Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study
JungHee Koh¹, Ji Hyeon Ju², Min Kyung Chung³, Ji Hun Kim³, Seung Min Jung⁴, Ji Yeon Lee², Jennifer Lee³, Seung-Ki Kwok⁵ and Sung-Hwan Park³, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than and those without RA, and are therefore exposed to Bisphosphonates (BPs) for longer.…
Abstract Number: 351 • 2015 ACR/ARHP Annual Meeting
Trabecular Bone Score Is Severely Affected in Male Patients with Chronic Obstructive Pulmonary Disease
Marta Arévalo Salaet¹, Enrique Casado Burgos¹, M Gallego¹, Luis Del Rio², Marta Larrosa³ and Jordi Gratacos⁴, ¹Hospital Universitari Parc Taulí, Sabadell, Spain, ²CETIR Medical Centre, Terrassa, Spain, ³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology, Hospital de Sabadell, Sabadell, Spain
Background/Purpose: Patients with chronic obstructive pulmonary disease (COPD) have a high risk of osteoporosis and fractures. In a cohort of male patients with COPD we…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 353 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
Hisaji Oshima¹, Mari Ushikubo¹, Kumiko Akiya¹, Ikuko Tanaka², Shigenori Tamaki² and Keisuke Izumi³, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Although weekly teriparatide (56.5ug, wTPTD) and denosmab (DMAB) have been developed as potent anti-osteoporotic agents, effects of these agents on prevention of osteoporotic fractures…
Abstract Number: 354 • 2015 ACR/ARHP Annual Meeting
Association Between Bone and Clinical Parameters in Ankylosing Spondylitis
Vladimira Boyadzhieva¹, Mariana Ivanova², Nikolay Stoilov¹, Rumen Stoilov³, Rasho Rashkov⁴, Didier Hans⁵ and Rozier Berengere⁵, ¹Rheumatology, University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ²University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, MHAT Sveti Ivan Rilski, Sofia, Bulgaria, ⁵Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatological disease of unknown origin that primarily affects the axial skeleton, including the sacroiliac joints and spine,…
Abstract Number: 355 • 2015 ACR/ARHP Annual Meeting
The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults
Leyre Riancho-Zarrabeitia¹, Maria T. García-Unzueta², Jair A. Tenorio³, Juan Gómez-Gerique⁴, Víctor L Ruiz Pérez³, Karen E. Heath³, Pablo Lapunzina³ and José A. Riancho⁵, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³Institute of Medical and Molecular Genetics. Hospital U. La Paz. IdiPAZ. Autonomous University of Madrid. CIBERER., Madrid, Spain, ⁴Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. University of Cantabria, Santander, Spain
Background/Purpose: Different from infantile forms, adult forms of hypophosphatasia have less severe manifestations and may go unrecognized. Low serum levels of alkaline phosphatase (ALP), the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].